Mirum Pharmaceuticals, Inc. announced the presentation of a series of analyses demonstrating further benefit of LIVMARLI® oral solution in patients with cholestatic pruritus associated with Alagille syndrome and for patients with progressive familial intrahepatic cholestasis, two rare debilitating liver diseases.
